pLenti-U6-tdTomato-P2A-BlasR (LRT2B) Citations (8)
Originally described in: Optimized base editors enable efficient editing in cells, organoids and mice.Zafra MP, Schatoff EM, Katti A, Foronda M, Breinig M, Schweitzer AY, Simon A, Han T, Goswami S, Montgomery E, Thibado J, Kastenhuber ER, Sanchez-Rivera FJ, Shi J, Vakoc CR, Lowe SW, Tschaharganeh DF, Dow LE Nat Biotechnol. 2018 Jul 3. pii: nbt.4194. doi: 10.1038/nbt.4194. PubMed Journal
Articles Citing pLenti-U6-tdTomato-P2A-BlasR (LRT2B)
| Articles |
|---|
| Base editing the mammalian genome. Schatoff EM, Zafra MP, Dow LE. Methods. 2019 Jul 15;164-165:100-108. doi: 10.1016/j.ymeth.2019.02.022. Epub 2019 Mar 2. PubMed |
| Characterization of a small molecule inhibitor of disulfide reductases that induces oxidative stress and lethality in lung cancer cells. Johnson FD, Ferrarone J, Liu A, Brandstadter C, Munuganti R, Farnsworth DA, Lu D, Luu J, Sihota T, Jansen S, Nagelberg A, Shi R, Forcina GC, Zhang X, Cheng GSW, Spencer Miko SE, de Rappard-Yuswack G, Sorensen PH, Dixon SJ, Guha U, Becker K, Djaballah H, Somwar R, Varmus H, Morin GB, Lockwood WW. Cell Rep. 2022 Feb 8;38(6):110343. doi: 10.1016/j.celrep.2022.110343. PubMed |
Base editing sensor libraries for high-throughput engineering and functional analysis of cancer-associated single nucleotide variants.
Sanchez-Rivera FJ, Diaz BJ, Kastenhuber ER, Schmidt H, Katti A, Kennedy M, Tem V, Ho YJ, Leibold J, Paffenholz SV, Barriga FM, Chu K, Goswami S, Wuest AN, Simon JM, Tsanov KM, Chakravarty D, Zhang H, Leslie CS, Lowe SW, Dow LE.
Nat Biotechnol. 2022 Feb 14. pii: 10.1038/s41587-021-01172-3. doi: 10.1038/s41587-021-01172-3.
PubMed
Associated Plasmids |
| RNAi-Mediated Screen of Primary AML Cells Nominates MDM4 as a Therapeutic Target in NK-AML with DNMT3A Mutations. Sidorova OA, Sayed S, Paszkowski-Rogacz M, Seifert M, Camgoz A, Roeder I, Bornhauser M, Thiede C, Buchholz F. Cells. 2022 Mar 2;11(5). pii: cells11050854. doi: 10.3390/cells11050854. PubMed |
| Efficient Correction of Oncogenic KRAS and TP53 Mutations through CRISPR Base Editing. Sayed S, Sidorova OA, Hennig A, Augsburg M, Cortes Vesga CP, Abohawya M, Schmitt LT, Surun D, Stange DE, Mircetic J, Buchholz F. Cancer Res. 2022 Sep 2;82(17):3002-3015. doi: 10.1158/0008-5472.CAN-21-2519. PubMed |
| LKB1-Dependent Regulation of TPI1 Creates a Divergent Metabolic Liability between Human and Mouse Lung Adenocarcinoma. Stein BD, Ferrarone JR, Gardner EE, Chang JW, Wu D, Hollstein PE, Liang RJ, Yuan M, Chen Q, Coukos JS, Sindelar M, Ngo B, Gross SS, Shaw RJ, Zhang C, Asara JM, Moellering RE, Varmus H, Cantley LC. Cancer Discov. 2023 Apr 3;13(4):1002-1025. doi: 10.1158/2159-8290.CD-22-0805. PubMed |
| LKB1 suppresses growth and promotes the internalization of EGFR through the PIKFYVE lipid kinase. Ferrarone JR, Thomas J, Unni AM, Zheng Y, Nagiec MJ, Gardner EE, Mashadova O, Li K, Koundouros N, Montalbano A, Mustafa M, Cantley LC, Blenis J, Sanjana NE, Varmus H. bioRxiv [Preprint]. 2023 Oct 20:2023.10.19.563158. doi: 10.1101/2023.10.19.563158. PubMed |
| Genome-wide CRISPR screens in spheroid culture reveal that the tumor suppressor LKB1 inhibits growth via the PIKFYVE lipid kinase. Ferrarone JR, Thomas J, Unni AM, Zheng Y, Nagiec MJ, Gardner EE, Mashadova O, Li K, Koundouros N, Montalbano A, Mustafa M, Cantley LC, Blenis J, Sanjana NE, Varmus H. Proc Natl Acad Sci U S A. 2024 May 21;121(21):e2403685121. doi: 10.1073/pnas.2403685121. Epub 2024 May 14. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.